
Winners and losers at #ESMO18
MUNICH — AstraZeneca has followed up on its breakthrough approval for Lynparza — the first of the PARP wave that arrived on the market 4 years ago — with the rollout of impressive frontline data for ovarian cancer.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.